商业化装机方面，公司旗下各产品共完成商业化装机150余台。其中，图迈全球范围内的商业化装机量 已突破百台，该百台装机均已取得用户签署的装机验收报告。公司称，图迈成为首个实现百台商业化装 机的国产腔镜手术机器人，不仅证明其已具备行业基础设施级的系统可靠性与临床稳定性，也标志着其 在质量合规、生产工艺、工程验证、系统交付、临床适配及全流程保障能力等关键体系上实现了全面跃 升。 在国内市场，图迈在头部公立医院及高端非公立医院市场均取得突破性进展，装机医院中百强医院占比 已达到23%，三甲医院占比超过90%，图迈已逐步形成以临床价值驱动、专业能力沉淀为核心的高质量 装机格局。截至目前，图迈海外市场布局已广泛覆盖亚洲、欧洲、非洲、大洋洲、南美洲的40余个国家 和地区，获得当地顶级机构的认可，并已在15个国家实现"多台销售、多院装机"，实现在全球不同地域 成熟医疗体系内的常态化、网络化、规模化使用。 公司表示，这一里程碑式突破，不仅标志着国产手术机器人在微创与微无创诊疗关键技术路径上实现系 统性全覆盖，也意味着中国在该领域已无关键技术"空白"。在此基础上，一个由微创机器人持续构建， 以体系化创新为内核、以平台化能力输出为 ...

Core Insights - MicroPort Robotics has announced that its independently developed bronchoscopic surgical robot has received approval from the National Medical Products Administration for market launch [1] - This approval increases the total number of surgical robots approved for market by MicroPort Robotics to seven, making it the first and only company globally to achieve commercialization of surgical robots across all product categories [1] Company Developments - The newly approved bronchoscopic surgical robot is developed by Shanghai MicroPort MicroRobotics Co., Ltd., a subsidiary of MicroPort Robotics [1] - The achievement signifies a significant milestone in the company's strategy to expand its product offerings in the surgical robotics sector [1] Industry Impact - MicroPort Robotics' accomplishment highlights its leadership position in the surgical robotics market, potentially influencing competitive dynamics within the industry [1] - The approval of the new product may enhance the company's market share and drive further innovation in surgical robotics [1]

Group 1 - The core viewpoint of the news is that MicroPort Robotics has received approval from the National Medical Products Administration (NMPA) for its self-developed bronchoscopic surgical robot, UniPathTM, marking a significant milestone in the field of surgical robotics and indicating comprehensive coverage of key technologies in minimally invasive diagnosis and treatment [1] - With this approval, the number of surgical robot products approved for market by the company has increased to seven, making it the first and only company globally to commercialize products across all five major categories of surgical robots [1] - The newly approved UniPathTM is a non-invasive robotic surgical platform that utilizes a highly flexible, slender robotic catheter to access hard-to-reach narrow lesions through natural body cavities, which is crucial for the early diagnosis and treatment of early-stage lung cancer [1] Group 2 - As a representative of natural orifice transluminal endoscopic surgery (NOTES) robots, the bronchoscopic surgical robot is seen as a key technological pathway for advancing minimally invasive surgery towards "less trauma and no external incisions" [2] - UniPathTM integrates critical technologies such as precise robotic control, flexible catheter navigation, intelligent path planning, and closed-loop control, providing a comprehensive solution for complex pulmonary anatomy [2] - The system enhances accessibility to fine bronchi and deep lung segments, supporting higher certainty in reaching and performing puncture and ablation operations on small lesions under dynamic breathing conditions, thereby continuously expanding the clinical application boundaries of bronchoscopic interventions [2]

作为经自然腔道手术机器人的典型代表，支气管镜手术机器人被视为推动微创外科向"更少创伤、无体 表切口"演进的重要技术路径，亦是近年来呼吸介入领域发展最快的智慧微创诊疗平台之一。 智通财经APP讯，微创机器人-B(02252)发布公告，由本集团自主研发的支气管镜手术机器人独道 ®UniPathTM电子支气管镜手术导航系统(独道)正式获得国家药品监督管理局(NMPA)批准。 本次独道获得NMPA批准，是本集团引领全球手术机器人领域技术与应用发展的里程碑式突破，也标志 着国产手术机器人在微无创诊疗关键技术路径上实现系统性全覆盖。至此，本集团在手术机器人领域获 批上市的产品数量增至7 款，成为全球首家、也是目前唯一一家实现手术机器人"五大黄金赛道"全赛道 产品商业化上市的企业。一个由本集团持续构建，以体系化创新为内核、以平台化能力输出为支撑，兼 具系统完整性、技术纵深与可持续演进能力的国产手术机器人生态体系，正加速成型并迈入规模化发展 阶段。 最新获批的独道是一个无创经自然腔道机器人手术平台，其具有超柔顺，超纤细蛇形机器人导管，可通 过人体自然腔道，以无体表创伤的方式进入难以触及的狭窄病灶空间，对肺部微小结节等癌症早期 ...

Core Insights - The company, MicroPort Robotics-B (02252.HK), has received approval from the National Medical Products Administration (NMPA) for its self-developed bronchoscopic surgical robot, UniPathTM, marking a significant milestone in the field of surgical robotics [1] - This approval increases the number of products approved for market by the company in the surgical robotics sector to seven, making it the first and only company globally to commercialize products across all five major categories of surgical robots [1] - The newly approved UniPathTM is a non-invasive robotic surgical platform that utilizes a highly flexible, slender robotic catheter to access hard-to-reach areas within the body through natural orifices, which is crucial for early diagnosis and treatment of small lung nodules and early-stage cancers [1] Industry Insights - As a representative of natural orifice surgical robots, bronchoscopic surgical robots are seen as a key technological pathway for advancing minimally invasive surgery towards "less trauma and no external incisions" [2] - UniPathTM integrates critical technologies such as precise robotic control, flexible catheter navigation, intelligent path planning, and closed-loop control, providing a comprehensive solution for complex pulmonary anatomy [2] - The system enhances accessibility to fine bronchi and deep lung segments, supporting higher certainty in reaching and performing puncture and ablation operations on small lesions under dynamic respiratory conditions, thereby expanding the clinical application boundaries of bronchoscopic interventions [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2252） 自願性公告 獨道電子支氣管鏡手術導航系統 獲得國家藥品監督管理局註冊批准 本公告由上海微創醫療機器人（集團）股份有限公司（「本公司」與其附屬公司合 稱「本集團」）自願作出，以向本公司股東及潛在投資者提供有關本集團的最新 業務進展情況。 本公司董事會（「董事會」）欣然宣佈由本集團自主研發的支氣管鏡手術機器人 獨道®UniPathTM電子支氣管鏡手術導航系統（「獨道」）正式獲得國家藥品監督管 理局（「NMPA」）批准。 對本公司的影響 本次獨道獲得NMPA批准，是本集團引領全球手術機器人領域技術與應用發展 的里程碑式突破，也標誌著國產手術機器人在微無創診療關鍵技術路徑上實 現系統性全覆蓋。至此，本集團在手術機器人領域獲批上市的產品數量增至7 款，成為全球首家、也是目前唯一一家實現手術機器人「五大黃金賽道」全賽道 產品商業化上市的企業。一個由 ...

Company News - Bank of China (03988.HK) has completed the issuance of 50 billion yuan in subordinated capital bonds, with the funds intended to supplement the bank's Tier 2 capital, subject to applicable laws and regulatory approvals [2] - Huadian International Power (01071.HK) has fully commissioned two 660,000 kW ultra-supercritical units at the Huadian Longkou Phase IV project, which integrates advanced technologies and achieves energy consumption levels comparable to the best in the domestic market, enhancing grid stability and local heating and industrial steam supply [2] - Weisheng Holdings (03393.HK) has entered into a capital increase agreement with Boyu Capital, with Boyu investing a total of 380 million yuan to subscribe for additional shares in its subsidiary [3] - Green Leaf Pharmaceutical (02186.HK) has granted Enhua exclusive commercialization rights for three long-acting injectable antipsychotic products in mainland China [4] - Heng Rui Medicine (01276.HK) has had its injectable SHR-A1904 included in the list of breakthrough therapy products by the drug review center [5] - Youzhiyou Biotechnology-B (02496.HK) has received IND approval from NMPA for Y225 (Aimeisai monoclonal antibody injection) [6] - MicroPort Robotics-B (02252.HK) has achieved a global commercialization milestone with over 100 installations of its Tumi laparoscopic surgical robot [7] - Gao Shan Enterprises (00616.HK) has signed a memorandum of understanding to establish a joint venture to participate in or invest in stablecoins and blockchain-related industries [8] - Energy International Investment (00353.HK) plans to issue a total of 1.035 billion subscription shares at a discount of approximately 18.33%, aiming to raise about 254 million HKD [9] Buyback Activities - Tencent Holdings (00700.HK) has repurchased approximately 636 million HKD worth of 1.056 million shares at prices ranging from 598 to 604 HKD [10] - Xiaomi Group-W (01810.HK) has spent 149 million HKD to repurchase 3.8 million shares at prices between 39.08 and 39.26 HKD [11] - China COSCO Shipping Holdings (01919.HK) has repurchased shares worth approximately 27.225 million HKD, acquiring 1.96 million shares at prices from 13.82 to 13.95 HKD [12] - Kuaishou-W (01024.HK) has repurchased shares for about 29.9896 million HKD, buying 464,000 shares at prices between 64.05 and 64.9 HKD [13]

Core Viewpoint - The article highlights the successful commercialization and global expansion of the TUMAI® robotic surgical system, marking a significant milestone in China's medical technology innovation and its role in global healthcare [2][4]. Group 1: Commercialization Milestones - The TUMAI® robotic surgical system has officially landed in Brazil at Hospital Unimed Foz do Iguaçu, marking the 100th commercial installation globally, with over 160 cumulative orders to date [2][10]. - The rapid growth in orders from October to December 2025, from over 100 to 160+, showcases the unprecedented commercialization speed of the TUMAI® system [10]. - The TUMAI® robot has achieved a significant market presence, becoming the first domestic laparoscopic surgical robot to reach 100 commercial installations, indicating its reliability and clinical stability [2][10]. Group 2: Strategic Partnerships and Market Integration - Hospital Unimed Foz do Iguaçu represents a key part of Brazil's Unimed healthcare system, the largest cooperative healthcare system in Brazil, indicating TUMAI®'s deep integration capabilities within established healthcare frameworks [8]. - The successful installation at this flagship hospital demonstrates TUMAI®'s ability to align with procurement models, maintenance costs, and training systems, enhancing its market expansion potential in Brazil and Latin America [8][10]. - The TUMAI® robot's entry into various international markets, including partnerships with top medical institutions in countries like Belgium, Italy, and India, reflects its growing global footprint and acceptance [25][29]. Group 3: Ecosystem Development and Technological Advancements - A multi-layered robotic surgical ecosystem is forming, integrating top experts, regional medical centers, and grassroots hospitals, facilitating the widespread adoption of robotic surgery [32]. - The TUMAI® system has enabled remote surgical capabilities across various regions, including successful cross-border surgeries in the Middle East and Europe, enhancing the accessibility of high-quality surgical resources [34][41]. - The article emphasizes the importance of TUMAI®'s technological advancements and its ability to adapt to diverse regulatory and clinical environments, establishing a competitive edge in the global market [42].

Core Insights - The company has reported a significant increase in cumulative orders for its core products, surpassing 230 units, with over 160 commercial orders for the TUMAI surgical robot, including nearly 120 new orders this year [1] - The TUMAI robot has achieved over 100 commercial installations globally, all of which have received signed acceptance reports from users, aligning with the company's revenue recognition policy [1] - TUMAI is the first domestic endoscopic surgical robot to reach 100 commercial installations, demonstrating its reliability and clinical stability, as well as advancements in quality compliance and production processes [1] Market Performance - In the domestic market, TUMAI has made significant progress in top public hospitals and high-end private hospitals, with 23% of installed hospitals being top-tier hospitals and over 90% being tertiary hospitals [2] - The company has established a high-quality installation pattern driven by clinical value and professional capability, enabling remote teaching, technical support, and collaborative surgeries across various hospital levels [2] - TUMAI's global market share is on the rise, with a rapidly developing ecosystem for robotic surgeries that integrates academic, technical, and clinical systems, covering over 40 countries and regions [2]

Core Insights - The company, MicroPort Scientific Corporation, reported that its cumulative order volume for core products in the fields of endoscopy, orthopedics, and vascular intervention has exceeded 230 units [1] - The Tumi endoscopic surgical robot has achieved over 160 commercial orders globally, with nearly 120 new orders acquired this year, positioning it among the top two in global order volume for 2025 [1] - The company has completed over 150 commercial installations of its products, with Tumi surpassing 100 installations, all of which have received signed acceptance reports from users [1] Product Performance - Tumi is the first domestically produced endoscopic surgical robot to achieve over 100 commercial installations, demonstrating its reliability and clinical stability at an industry infrastructure level [1] - The advancements in Tumi's quality compliance, production processes, engineering validation, system delivery, clinical adaptation, and overall process assurance capabilities signify a comprehensive leap in its operational standards [1]